Morgan Stanley Reiterates Overweight on Immunocore Hldgs, Maintains $79 Price Target
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Andrew Galler has reiterated an Overweight rating on Immunocore Hldgs (NASDAQ:IMCR) and maintained a $79 price target.
July 31, 2023 | 1:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Morgan Stanley has reiterated an Overweight rating on Immunocore Hldgs and maintained a $79 price target.
The reiteration of an Overweight rating by Morgan Stanley indicates a positive outlook for Immunocore Hldgs. The maintained price target of $79 suggests that the analyst believes the stock is still undervalued, which could lead to upward pressure on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100